Details of the Drug Combination

General Information of Drug Combination (ID: DCN8W39)

Drug Combination Name
Tazobactam Ceftolozane sulfate
Indication
Disease Entry Status REF
Other Infectious Diseases Phase 2 [1]
Component Drugs Tazobactam   DM3XNUI Ceftolozane sulfate   DMYGEH7
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Tazobactam
Disease Entry ICD 11 Status REF
Appendicitis DB10 Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Peritonitis N.A. Approved [2]
Staphylococcus aureus infection N.A. Approved [2]
Pelvic inflammatory disease GA05 Investigative [2]
Tazobactam Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus Beta-lactamase (Stap-coc blaZ) TTHI19T BLAC_STAAU Inhibitor [5]
------------------------------------------------------------------------------------
Tazobactam Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Beta-lactamase (blaB) DEEZ5CV BLO1_KLEOX Metabolism [6]
Beta-lactamase (blaB) DEYIEO5 AMPC_SERMA Metabolism [7]
------------------------------------------------------------------------------------
Indication(s) of Ceftolozane sulfate
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 4 [4]
Ceftolozane sulfate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Penicillin binding protein (Bact PBP) TTJP4SM NOUNIPROTAC Modulator [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03485950) Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
2 Tazobactam FDA Label
3 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
4 ClinicalTrials.gov (NCT02421120) Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients. U.S. National Institutes of Health.
5 Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
6 Characterization of piperacillin/tazobactam-resistant klebsiella oxytoca recovered from a nosocomial outbreak. PLoS One. 2015 Nov 5;10(11):e0142366.
7 Determination of the antibiotic resistance rates of Serratia marcescens isolates obtained from various clinical specimens. Niger J Clin Pract. 2019 Jan;22(1):125-130.
8 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.